Sweden's Alligator Bioscience Q2 loss widens, no sales

Alligator Bioscience AB

26/08/2026 07:09

Overview
Sweden biotech firm reported no Q2 net sales and a wider net loss yr/yr
Company discontinued mitazalimab development to focus on HLX22 royalty potential
Rights issue of SEK 125.6 mln announced, pending shareholder approval

Outlook
Alligator Bioscience will discontinue independent development of mitazalimab and refocus on HLX22
Company plans to out-license or divest mitazalimab in the near term
Alligator announced a rights issue of units of SEK 125.6 mln, pending shareholder approval

Result Drivers
STRATEGIC REFOCUS - Co discontinued independent development of mitazalimab to prioritize future royalty potential from HLX22
HLX22 PROGRESS - Partner Henlius dosed first patients in all regions for global Phase 3 study and reported extended progression-free survival in long-term follow-up

Company press release: ID:nMFNbdnts7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
 
SEK 0.06
 
Q2 Net Loss
 
SEK 37.80 mln
 
Q2 EBIT
 
-SEK 36.20 mln
 

Analyst Coverage
Wall Street's median 12-month price target for Alligator Bioscience AB is SEK0.30, about 960.1% above its August 25 closing price of SEK0.03

Reuters Recommended Reads
Aug 25 - Sweden's Isofol Medical reports no Q2 revenue, net loss widens
Aug 25 - China's Clover Biopharma H1 revenue drops sharply, flags going-concern doubt
Aug 25 - Molecular Partners H1 net loss narrows on lower R&D expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)